Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > generic

: Calcitriol (1,25-dihydroxyvitamin D3)

or None

& routes: IV infusion every 4 weeks

Use the filters below to narrow your results.

Aduhelm (1) · Kisunla (1)

Anti-amyloid beta (Aβ) monoclonal antibody (2) · targets pyroglutamated Aβ in plaques (1)

None (1) · Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1)

Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) · Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1)

700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) · Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)

350 mg/20 mL vial for IV infusion (1) · Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)

1400 mg q4w (1) · Withdrawn 2024 (1)

Amyloid PET clearance within months; cognitive benefit over 18 months (1) · PET Aβ reduction over months (1)

Treatment can be discontinued upon achieving amyloid clearance (1) · Withdrawn (1)

~12.1 days (1) · ~25 days (1)

100% (IV) (2)

Discontinued/withdrawn (1) · Limited data (1)

Rx; ARIA monitoring required (1) · Withdrawn from US market January 2024 (1)

Showing below up to 2 results in range #1 to #2.

A

Aducanumab

D

Donanemab

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"